Antipodes Partners awarded

2026 Fund Manager of the Year, Australia

Morningstar Awards 2026 © Morningstar, Inc. All Rights Reserved.

Tomorrow’s winners; five mispriced opportunities

Global equities had a strong 2023. Performance for most of the year was driven by the seven largest tech stocks. However, the back end of the year saw an increase in breadth as the 2023 laggards began to rally.

Medical-device sector well placed to shine in 2024

The media hype around booming demand for glucagon-like peptide 1 (GLP-1) drugs, and their weight-loss abilities, has distracted the attention of healthcare investors from the potential of medical-device companies.

Shopping for UK stock bargains

Negative sentiment is weighing on the UK stock market, and that means we can find attractively valued, well-managed businesses trading at a large discount to counterparts in other markets.

Focusing on tomorrow’s winners

Every investor knows that past performance isn’t a reliable indicator of future results, yet many are attracted to established winners whose stock price may have been hyped to unrealistic heights.

The global economic outlook supports stock pickers

The performance of global stock markets this year has been led by a handful of stocks. With share prices at elevated levels and the economic outlook deteriorating, investors should focus on individual corporate fundamentals.

Now available on the ASX: the Antipodes Global SMID Active ETF (ASX:MIDS)

X